IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma
Glioma is characterized by strong immunosuppression and excessive angiogenesis. Based on existing reports, it can be speculated that the resistance to anti-angiogenic drug vascular endothelial growth factor A (VEGFA) antibody correlates to the induction of novel immune checkpoint indoleamine 2,3-dio...
المؤلفون الرئيسيون: | Zikang Xing, Xuewen Li, Zhen Ning Tony He, Xin Fang, Heng Liang, Chunxiang Kuang, Aiying Li, Qing Yang |
---|---|
التنسيق: | مقال |
اللغة: | English |
منشور في: |
MDPI AG
2024-06-01
|
سلاسل: | Pharmaceutics |
الموضوعات: | |
الوصول للمادة أونلاين: | https://www.mdpi.com/1999-4923/16/7/870 |
مواد مشابهة
-
TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
حسب: V. A. Kozlov, وآخرون
منشور في: (2017-07-01) -
On the nonredundant roles of TDO2 and IDO1
حسب: Paolo ePuccetti
منشور في: (2014-10-01) -
Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use
حسب: Ganiyu Olatunbosun Arinola, وآخرون
منشور في: (2023-01-01) -
The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2)
حسب: Chiara Suvieri, وآخرون
منشور في: (2024-11-01) -
Tryptophan-degrading enzymes in tumoral immune resistance
حسب: Nicolas van Baren, وآخرون
منشور في: (2016-11-01)